A/DT
Universal/JJ
Analysis/NN
Pipeline/NN
for/IN
Hybrid/NN
Capture-Based/JJ
Targeted/VBN
Sequencing/NN
Data/NNS
with/IN
Unique/JJ
Molecular/JJ
Indexes/NNS
./.
====================
Hybrid/NN
capture-based/VBN
targeted/VBN
sequencing/NN
is/VBZ
being/VBG
used/VBN
increasingly/RB
for/IN
genomic/JJ
variant/JJ
profiling/VBG
in/IN
tumor/NN
patients/NNS
./.
====================
Unique/JJ
molecular/JJ
index/NN
(/(
UMI/NN
)/)
technology/NN
has/VBZ
recently/RB
been/VBN
developed/VBN
and/CC
helps/VBZ
to/TO
increase/VB
the/DT
accuracy/NN
of/IN
variant/JJ
calling/JJ
by/IN
minimizing/VBG
polymerase/NN
chain/NN
reaction/NN
biases/VBZ
and/CC
sequencing/NN
errors/NNS
./.
====================
However/RB
,/,
UMI-adopted/JJ
targeted/VBN
sequencing/NN
data/NNS
analysis/NN
is/VBZ
slightly/RB
different/JJ
from/IN
the/DT
methods/NNS
for/IN
other/JJ
types/NNS
of/IN
omics/NNS
data/NNS
,/,
and/CC
its/PRP$
pipeline/NN
for/IN
variant/JJ
calling/JJ
is/VBZ
still/RB
being/VBG
optimized/VBN
in/IN
various/JJ
study/NN
groups/NNS
for/IN
their/PRP$
own/JJ
purposes/NNS
./.
====================
Due/IN
to/TO
this/DT
provincial/JJ
usage/NN
of/IN
tools/NNS
,/,
our/PRP$
group/NN
built/NN
an/DT
analysis/NN
pipeline/NN
for/IN
global/JJ
application/NN
to/TO
many/JJ
studies/NNS
of/IN
targeted/VBN
sequencing/NN
generated/VBN
with/IN
different/JJ
methods/NNS
./.
====================
First/RB
,/,
we/PRP
generated/VBD
hybrid/NN
capture-based/VBD
data/NNS
using/VBG
genomic/JJ
DNA/NN
extracted/VBN
from/IN
tumor/NN
tissues/NNS
of/IN
colorectal/JJ
cancer/NN
patients/NNS
./.
====================
Sequencing/NN
libraries/NNS
were/VBD
prepared/VBN
and/CC
pooled/JJ
together/RB
,/,
and/CC
an/DT
8-plexed/JJ
capture/NN
library/NN
was/VBD
processed/VBN
to/TO
the/DT
enrichment/JJ
step/NN
before/IN
150-bp/JJ
paired-end/NN
sequencing/NN
with/IN
Illumina/NN
HiSeq/JJ
series/NN
./.
====================
For/IN
the/DT
analysis/NN
,/,
we/PRP
evaluated/VBD
several/JJ
published/VBN
tools/NNS
./.
====================
We/PRP
focused/VBD
mainly/RB
on/IN
the/DT
compatibility/NN
of/IN
the/DT
input/NN
and/CC
output/NN
of/IN
each/DT
tool/NN
./.
====================
Finally/RB
,/,
our/PRP$
laboratory/NN
built/NN
an/DT
analysis/NN
pipeline/NN
specialized/VBN
for/IN
UMI-adopted/JJ
data/NNS
./.
====================
Through/IN
this/DT
pipeline/NN
,/,
we/PRP
were/VBD
able/JJ
to/TO
estimate/VB
even/RB
on-target/JJ
rates/NNS
and/CC
filtered/JJ
consensus/NN
reads/VBZ
for/IN
more/RBR
accurate/JJ
variant/JJ
calling/JJ
./.
====================
These/DT
results/NNS
suggest/VBP
the/DT
potential/JJ
of/IN
our/PRP$
analysis/NN
pipeline/NN
in/IN
the/DT
precise/JJ
examination/NN
of/IN
the/DT
quality/NN
and/CC
efficiency/NN
of/IN
conducted/JJ
experiments/NNS
./.
====================
The/DT
development/NN
of/IN
next-generation/NN
sequencing/NN
(/(
NGS/NN
)/)
has/VBZ
brought/VBN
remarkable/JJ
growth/NN
in/IN
our/PRP$
understanding/NN
of/IN
human/JJ
genome/NN
variants/NNS
through/IN
comprehensive/JJ
characterization/NN
./.
====================
On/IN
top/NN
of/IN
that/DT
,/,
various/JJ
efforts/NNS
have/VBP
been/VBN
made/VBN
to/TO
find/VB
associations/NNS
of/IN
these/DT
understandings/NNS
with/IN
diseases/NNS
,/,
including/VBG
cancers/NNS
[/(
1/CD
]/)
./.
====================
Particularly/RB
,/,
detecting/VBG
various/JJ
mutations/NNS
,/,
including/VBG
somatic/JJ
mutations/NNS
,/,
is/VBZ
essential/JJ
to/TO
comprehend/VB
the/DT
cancer/NN
genome/NN
[/(
2/CD
]/)
./.
====================
However/RB
,/,
this/DT
is/VBZ
one/CD
of/IN
the/DT
most/JJS
challenging/VBG
parts/NNS
in/IN
studying/VBG
cancer/NN
,/,
because/IN
somatic/JJ
mutations/NNS
are/VBP
sporadic/JJ
among/IN
healthy/JJ
cells/NNS
[/(
3/CD
]/)
,/,
and/CC
therefore/RB
,/,
variants/NNS
with/IN
low/JJ
allelic/JJ
fractions/NNS
are/VBP
hard/RB
to/TO
track/VB
down/RB
[/(
4/CD
]/)
./.
====================
Fortunately/RB
,/,
targeted/VBN
sequencing/NN
has/VBZ
been/VBN
a/DT
great/JJ
support/VBP
to/TO
overcome/VB
these/DT
difficulties/NNS
./.
====================
Compared/VBN
to/TO
whole-genome/DT
sequencing/VBG
,/,
targeted/VBN
sequencing/VBG
has/VBZ
several/JJ
advantages/NNS
in/IN
many/JJ
aspects/NNS
:/:
high/JJ
coverage/RB
data/NNS
could/MD
be/VB
generated/VBN
at/IN
a/DT
more/RBR
reasonable/JJ
price/RB
[/(
5/CD
]/)
;/:
low-frequency/RB
variants/NNS
could/MD
be/VB
detected/VBN
with/IN
this/DT
ultra-deep/JJ
sequencing/VBG
[/(
6/CD
]/)
;/:
and/CC
different/JJ
types/NNS
of/IN
mutations/NNS
,/,
such/JJ
as/IN
single-nucleotide/JJ
variants/NNS
,/,
short/JJ
indels/VBZ
(/(
insertion/NN
and/CC
deletions/NNS
)/)
,/,
structure/NN
variations/NNS
,/,
and/CC
copy/NN
number/NN
alterations/NNS
,/,
can/MD
be/VB
examined/VBN
via/IN
targeted/VBN
sequencing/VBG
[/(
7/CD
]/)
./.
====================
Therefore/RB
,/,
many/JJ
laboratories/NNS
in/IN
both/CC
academia/NN
and/CC
the/DT
medical/JJ
industry/NN
are/VBP
making/VBG
efforts/NNS
to/TO
develop/VB
their/PRP$
own/JJ
gene/NN
panels/NNS
with/IN
various/JJ
sizes/NNS
./.
====================
However/RB
,/,
the/DT
next/JJ
predicament/JJ
is/VBZ
the/DT
analysis/NN
of/IN
the/DT
targeted/VBN
sequencing/NN
data/NNS
,/,
since/IN
the/DT
variants/NNS
revealed/VBD
in/IN
the/DT
data/NNS
are/VBP
hard/VBN
to/TO
discriminate/VB
from/IN
false-positive/JJ
errors/NNS
./.
====================
In/IN
detail/NN
,/,
innate/JJ
sequencing/NN
errors/NNS
and/CC
early/JJ
cycle/NN
polymerase/NN
chain/NN
reaction/NN
(/(
PCR/NN
)/)
biases/VBZ
during/IN
library/NN
amplification/NN
or/CC
target/NN
enrichment/JJ
could/MD
be/VB
considered/VBN
super/IN
or/CC
rare/JJ
mutations/NNS
during/IN
the/DT
variant/JJ
calling/JJ
process/NN
./.
====================
To/TO
overcome/VB
this/DT
erroneous/JJ
algorithm/NN
,/,
unique/JJ
molecular/JJ
index/NN
(/(
UMI/NN
)/)
technology/NN
was/VBD
recently/RB
developed/VBD
[/(
8/CD
]/)
./.
====================
UMIs/NNS
,/,
as/IN
8–9-bp/JJ
random/JJ
oligonucleotides/NNS
,/,
barcode/JJ
a/DT
single/JJ
DNA/NN
molecule/NN
and/CC
index/NN
replicates/VBZ
generated/VBN
from/IN
the/DT
same/JJ
DNA/NN
templates/NNS
during/IN
PCR/NN
amplification/NN
./.
====================
Several/JJ
proof-of-concept/IN
studies/NNS
have/VBP
proven/VBN
the/DT
error/NN
correction/NN
mechanism/NN
of/IN
the/DT
UMI/NN
[/(
6/CD
,/,
9–13/CD
]/)
,/,
and/CC
they/PRP
revealed/VBD
that/IN
PCR/NN
biases/NNS
and/CC
sequencing/NN
errors/NNS
were/VBD
compensated/VBN
during/IN
consensus/NN
sequence/NN
extraction/NN
from/IN
reads/VBZ
with/IN
the/DT
same/JJ
UMI/NN
tags/NNS
[/(
6/CD
]/)
./.
====================
Nevertheless/RB
,/,
analyzing/VBG
data/NNS
with/IN
UMI/NN
is/VBZ
still/RB
a/DT
tedious/JJ
task/NN
[/(
8/CD
]/)
./.
====================
In/IN
other/JJ
words/NNS
,/,
some/DT
UMI-analyzing/VBG
and/CC
variant/JJ
calling/JJ
tools/NNS
have/VBP
limitations/NNS
in/IN
their/PRP$
broad/JJ
application/NN
to/TO
the/DT
data/NNS
generated/VBD
from/IN
different/JJ
hybrid/NN
capture/NN
platforms/NNS
or/CC
other/JJ
types/NNS
of/IN
sequencing/NN
data/NNS
,/,
such/JJ
as/IN
single-cell/JJ
sequencing/NN
./.
====================
In/IN
addition/NN
,/,
most/JJS
files/NNS
from/IN
each/DT
tool/NN
are/VBP
not/RB
compatible/JJ
with/IN
the/DT
tools/NNS
in/IN
different/JJ
pipelines/NNS
./.
====================
For/IN
example/NN
,/,
a/DT
recently/RB
developed/VBD
analysis/NN
tool/NN
,/,
named/VBN
smCounter2/NN
,/,
is/VBZ
a/DT
variant/JJ
caller/NN
and/CC
an/DT
analysis/NN
pipeline/NN
tool/NN
package/NN
for/IN
targeted/VBN
sequencing/NN
data/NNS
with/IN
UMIs/NNS
./.
====================
Purportedly/RB
,/,
this/DT
tool/NN
is/VBZ
specialized/VBN
to/TO
call/JJ
low-frequency/NN
variants/NNS
./.
====================
However/RB
,/,
the/DT
usage/NN
of/IN
smCounter2/NN
is/VBZ
restricted/JJ
only/RB
to/TO
the/DT
data/NNS
generated/VBD
by/IN
the/DT
QIAGEN/NN
QIAseq/NN
DNA/NN
target/NN
enrichment/JJ
kit/NN
[/(
6/CD
]/)
./.
====================
In/IN
this/DT
study/NN
,/,
to/TO
build/JJ
a/DT
versatile/JJ
analysis/NN
pipeline/VBP
to/TO
apply/RB
to/TO
various/JJ
types/NNS
of/IN
hybrid/NN
capture-based/VBD
targeted/VBN
sequencing/NN
,/,
our/PRP$
laboratory/NN
evaluated/VBD
various/JJ
types/NNS
of/IN
analysis/NN
tools/NNS
,/,
like/IN
Fulcrum/JJ
genomics/NNS
(/(
fgbio/RB
,/,
https/RB
:/:
//github.com/fulcrum-genomics/fgbio/DT
)/)
,/,
Picard/NN
(/(
http/NN
:/:
//broadinstitute.github.io/picard/JJ
)/)
,/,
and/CC
the/DT
Genome/NN
Analysis/NN
Tool/NN
Kit/NN
(/(
GATK/NN
)/)
[/(
14/CD
]/)
./.
====================
We/PRP
put/VBP
our/PRP$
effort/NN
into/IN
optimizing/JJ
the/DT
pipeline/NN
so/RB
as/IN
to/TO
not/RB
make/VB
discrepancies/NNS
between/IN
the/DT
files/NNS
and/CC
enable/VBP
easier/RBR
interpretation/NN
of/IN
the/DT
results/NNS
./.
====================
Furthermore/RB
,/,
we/PRP
show/VBP
an/DT
example/NN
of/IN
how/WRB
targeted/VBN
sequencing/NN
experiments/NNS
can/MD
be/VB
investigated/VBN
for/IN
their/PRP$
quality/NN
from/IN
the/DT
analysis/NN
and/CC
how/WRB
we/PRP
could/MD
take/VB
points/NNS
from/IN
the/DT
results/NNS
analysis/NN
as/IN
feedback/NN
for/IN
the/DT
experiment/JJ
./.
====================
Sample/NN
preparation/NN
====================
Tumor/NN
tissues/NNS
were/VBD
dissected/VBN
from/IN
6/CD
different/JJ
colorectal/JJ
cancer/NN
patients/NNS
./.
====================
Tumor/NN
samples/NNS
were/VBD
labeled/VBN
from/IN
1T/NN
to/TO
7T/NN
,/,
and/CC
sample/NN
4T/NN
was/VBD
omitted/VBN
./.
====================
NA24385/CD
of/IN
the/DT
HapMap/NN
project/VB
and/CC
AccuRef/NN
Quan-Plex/NN
NGS/NN
Reference/NN
Standard/JJ
Genomic/JJ
DNA/NN
(/(
cat/NN
#/NN
ARF-1001G-1/NN
;/:
AccuRef/NN
,/,
Milpitas/NNS
,/,
CA/NNP
,/,
USA/NNP
)/)
were/VBD
used/VBN
as/IN
positive/JJ
controls/NNS
./.
====================
Probe/NN
design/NN
for/IN
hybrid/NN
capture/NN
====================
For/IN
hybrid/NN
capture/NN
,/,
all/DT
coding/VBG
sequences/NNS
of/IN
46/CD
genes/NNS
and/CC
non-coding/JJ
sequences/NNS
of/IN
some/DT
of/IN
those/DT
genes/NNS
were/VBD
targeted/VBN
./.
====================
Pre-designed/VBN
and/CC
customized/VBD
probe/NN
sets/NNS
were/VBD
manufactured/VBN
by/IN
Integrated/JJ
DNA/NN
Technologies/NNS
(/(
IDT/NN
,/,
Coralville/NN
,/,
IA/NN
,/,
USA/NN
)/)
./.
====================
Targeted/VBN
sequencing/NN
data/NNS
generation/NN
====================
To/TO
analyze/VB
UMI-adopted/JJ
targeted/VBN
sequencing/NN
data/NNS
,/,
we/PRP
generated/VBD
targeted/VBN
sequencing/NN
libraries/NNS
./.
====================
During/IN
library/NN
generation/NN
,/,
UMI/NN
sequences/NNS
were/VBD
integrated/VBN
,/,
along/IN
with/IN
the/DT
P5/NN
sequencing/NN
adapter/NN
./.
====================
Eight/CD
libraries/NNS
were/VBD
pooled/JJ
together/RB
into/IN
one/CD
1.7-mL/NN
microtube/NNS
,/,
and/CC
this/DT
8-plex/NN
pooled/JJ
library/NN
was/VBD
then/RB
hybridized/VBD
using/VBG
IDT/NN
xGen/NN
LockDown/JJ
pre-designed/custom/VBP
probes/NNS
./.
====================
Targeted/VBN
sequencing/NN
data/NNS
of/IN
hybrid-capture/NN
library/NN
were/VBD
generated/VBN
using/VBG
HiSeq/JJ
series/NN
by/IN
150-bp/JJ
paired-end/NN
sequencing/NN
./.
====================
Data/NNS
processing/NN
====================
Using/VBG
BclToFastq/JJ
,/,
the/DT
.bcl/JJ
file/JJ
was/VBD
processed/VBN
and/CC
divided/VBN
into/IN
fastq/JJ
files/NNS
of/IN
read/JJ
1/CD
(/(
R1/NN
)/)
,/,
read/VBN
2/CD
(/(
R2/NN
)/)
,/,
and/CC
UMI/NN
./.
====================
To/TO
generated/VBN
unmapped/VBD
bam/JJ
files/NNS
,/,
R1.fastq/NN
and/CC
R2.fastq/NN
files/NNS
were/VBD
processed/VBN
using/VBG
FastqToBam/JJ
(/(
Fulcrum/NN
Genomics/fgbio/NN
,/,
v0.7.0/CD
)/)
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
Unmapped.bam/JJ
file/JJ
was/VBD
then/RB
sorted/VBN
using/VBG
SortSam/JJ
(/(
Picard/NN
)/)
to/TO
sort/VB
files/NNS
compatible/JJ
with/IN
downstream/JJ
tools/NNS
./.
====================
UMI/NN
information/NN
was/VBD
annotated/VBN
via/IN
AnnotateBamWithUmis/NN
(/(
fgbio/NN
)/)
./.
====================
To/TO
use/VB
MergeBamAlignment/JJ
(/(
Picard/NN
)/)
to/TO
generate/VB
UMI-annotated/JJ
mapped/VBD
bam/RB
files/NNS
,/,
SamToFastq/NN
(/(
Picard/NN
)/)
generated/VBD
fastq/JJ
files/NNS
containing/VBG
UMI/NN
information/NN
./.
====================
Burrows-Wheeler/NN
Aligner/NN
(/(
BWA-mem/NN
,/,
v0.1.17/CD
)/)
aligned/VBD
reads/VBZ
to/TO
the/DT
hg38/NN
reference/VBP
genome/NN
[/(
15/CD
]/)
./.
====================
The/DT
unmapped/JJ
bam/JJ
files/NNS
(/(
output/RB
of/IN
Tool/NN
#/CD
3/CD
)/)
and/CC
the/DT
aligned/JJ
bam/JJ
file/JJ
(/(
the/DT
output/NN
of/IN
BWA-mem/JJ
)/)
were/VBD
merged/VBN
via/IN
MergeBamAlignment/JJ
(/(
Picard/NN
)/)
./.
====================
Mapped.bam/NN
file/JJ
was/VBD
then/RB
grouped/VBD
by/IN
GroupReadsByUmi/NN
(/(
fgbio/NN
)/)
according/VBG
to/TO
its/PRP$
RX-tagged/JJ
UMI/NN
sequence/NN
./.
====================
UMI/NN
family/NN
information/NN
was/VBD
then/RB
used/VBN
for/IN
grouping/VBG
and/CC
calling/JJ
consensus/NN
reads/VBZ
via/IN
CallMolecularConsensusReads/NNS
(/(
fgbio/NN
)/)
./.
====================
FilterConsensusReads/VBZ
(/(
fgbio/NN
)/)
filters/NNS
consensus/NN
reads/VBZ
to/TO
make/VB
bam/JJ
files/NNS
suitable/JJ
for/IN
further/JJ
variant/JJ
calling/JJ
./.
====================
As/IN
CallMolecularConsensusReads/VBZ
and/CC
FilterConsensusReads/VBZ
generated/VBN
unmapped/VBD
bam/JJ
files/NNS
,/,
converting/VBG
bam/JJ
files/NNS
to/TO
fastq/JJ
files/NNS
,/,
the/DT
mapping/NN
and/CC
merging/VBG
steps/NNS
were/VBD
repeated/VBN
for/IN
the/DT
variant/JJ
calling/JJ
in/IN
the/DT
following/VBG
step/NN
./.
====================
The/DT
overall/JJ
pipeline/NN
is/VBZ
shown/VBN
in/IN
Fig/NN
./.
====================
1/CD
./.
====================
Quality/NN
check/NN
====================
UmiAwareMarkDuplicateWithMateCigar/JJ
(/(
Picard/NN
)/)
counted/VBD
duplicates/VBZ
among/IN
the/DT
raw/NN
reads/VBZ
to/TO
estimate/VB
duplicate/VBP
rates/NNS
./.
====================
As/IN
this/DT
tool/NN
is/VBZ
still/RB
under/IN
development/NN
,/,
we/PRP
recommend/VBP
a/DT
regular/JJ
check/NN
with/IN
the/DT
developers/NNS
on/IN
further/JJ
validation/NN
./.
====================
To/TO
calculate/VB
on-target/JJ
rates/NNS
(/(
%/NN
)/)
,/,
CollectHsMetrics/NNS
(/(
Picard/NN
)/)
is/VBZ
used/VBN
to/TO
generate/VB
HsMetrics/NNS
./.
====================
By/IN
expanding/VBG
100/CD
bp/NN
of/IN
chromosome/NN
coordinates/VBZ
(/(
start/end/NN
site/NN
)/)
in/IN
target.bed/VBN
,/,
on-target/RB
%/NN
,/,
including/VBG
flanking/JJ
regions/NNS
,/,
was/VBD
calculated/VBN
using/VBG
the/DT
same/JJ
tool/NN
./.
====================
To/TO
calculate/VB
the/DT
read/JJ
coverage/VBP
,/,
the/DT
following/VBG
equation/NN
was/VBD
used/VBN
:/:
Coverage/NN
=/JJ
Read/NN
length/NN
(/(
bp/NN
)/)
×/CD
The/DT
number/NN
of/IN
reads/Genome/JJ
size/NN
(/(
bp/NN
)/)
./.
====================
According/VBG
to/TO
the/DT
manufacturer/NN
,/,
the/DT
genome/NN
size/NN
refers/VBZ
to/TO
the/DT
target/NN
size/NN
of/IN
the/DT
probes/NNS
./.
====================
First/RB
,/,
total/JJ
read/VBN
counts/NNS
were/VBD
counted/VBN
by/IN
either/CC
Picard/NN
tools/NNS
or/CC
fgbio/NN
tools/NNS
./.
====================
An/DT
8-plexed/JJ
hybrid/NN
capture/NN
library/NN
generated/VBN
100/CD
Gbp/JJ
data/NNS
,/,
and/CC
approximately/RB
15/CD
Gbp/JJ
data/NNS
were/VBD
generated/VBN
from/IN
each/DT
sample/NN
./.
====================
Considering/VBG
the/DT
fact/NN
that/IN
the/DT
target/NN
genome/NN
size/NN
is/VBZ
0.3/CD
Mbp/JJ
,/,
the/DT
read/JJ
coverages/VBZ
were/VBD
calculated/VBN
as/IN
50,000×/CD
to/TO
70,000×/CD
,/,
as/IN
shown/VBN
in/IN
Table/JJ
1/CD
./.
====================
As/IN
on-target/RB
rate/NN
(/(
%/NN
)/)
represents/VBZ
how/WRB
much/RB
the/DT
probes/NNS
attach/DT
to/TO
the/DT
target/NN
genomic/JJ
regions/NNS
and/CC
as/IN
calculating/JJ
on-target/JJ
rates/NNS
(/(
%/NN
)/)
refers/VBZ
to/TO
the/DT
efficiency/NN
of/IN
experiments/NNS
,/,
we/PRP
examined/VBD
the/DT
on-target/JJ
rate/NN
(/(
%/NN
)/)
./.
====================
We/PRP
were/VBD
able/JJ
to/TO
get/VB
37/CD
%/NN
on-target/JJ
rate/NN
,/,
average/NN
(/(
Table/JJ
1/CD
,/,
Fig/NN
./.
====================
2/CD
)/)
./.
====================
On-target/RB
rates/NNS
were/VBD
slightly/RB
increased/VBN
when/WRB
target/NN
regions/NNS
were/VBD
expanded/VBN
to/TO
flanking/JJ
regions/NNS
(/(
+100/CD
bp/NN
)/)
./.
====================
In/IN
addition/NN
,/,
each/DT
sample/NN
showed/VBD
a/DT
similar/JJ
on-target/JJ
%/NN
,/,
and/CC
this/DT
may/MD
suggest/VB
that/IN
the/DT
hybridization/NN
step/NN
of/IN
targeted/VBN
sequencing/NN
was/VBD
processed/VBN
with/IN
an/DT
even/RB
amount/NN
of/IN
each/DT
library/NN
./.
====================
Before/IN
removing/VBG
sequence/NN
duplicates/VBZ
,/,
we/PRP
estimated/VBD
duplicate/JJ
read/VBN
counts/NNS
via/IN
UmiAwareMarkDuplicateWithMateCigar/JJ
(/(
Picard/NN
)/)
./.
====================
We/PRP
could/MD
measure/VB
duplicate/VBP
rates/NNS
of/IN
>/JJR
70/CD
%/NN
of/IN
the/DT
reads/VBZ
(/(
Fig/NN
./.
====================
3/CD
)/)
./.
====================
Considering/VBG
the/DT
fact/NN
that/IN
the/DT
percent/JJ
duplicate/JJ
increases/VBZ
as/IN
the/DT
sequencing/NN
coverage/NN
rises/NNS
[/(
16/CD
]/)
,/,
an/DT
average/NN
73/CD
%/NN
of/IN
duplicates/NNS
indicates/VBZ
that/IN
the/DT
targeting/VBG
efficiency/NN
of/IN
the/DT
probes/NNS
was/VBD
high/JJ
in/IN
high-coverage/JJ
sequencing/NN
./.
====================
In/IN
addition/NN
,/,
as/IN
we/PRP
were/VBD
aware/RB
that/DT
an/DT
excess/NN
number/NN
of/IN
PCR/NN
cycles/NNS
during/IN
target/NN
enrichment/JJ
brings/NNS
severe/JJ
biases/NNS
[/(
17/CD
]/)
,/,
we/PRP
assumed/VBD
that/IN
the/DT
number/NN
of/IN
PCR/NN
cycles/NNS
during/IN
enrichment/JJ
was/VBD
moderate/JJ
./.
====================
Although/IN
duplicate/JJ
reads/VBZ
were/VBD
not/RB
discarded/VBN
in/IN
further/JJ
steps/NNS
,/,
by/IN
checking/VBG
duplicate/IN
rates/NNS
,/,
we/PRP
confirmed/VBD
that/IN
the/DT
number/NN
of/IN
PCR/NN
cycles/NNS
during/IN
library/NN
preparation/NN
and/CC
target/NN
enrichment/JJ
was/VBD
adequate/JJ
./.
====================
In/IN
addition/NN
,/,
we/PRP
were/VBD
able/JJ
to/TO
verify/VB
the/DT
ability/NN
to/TO
examine/VB
the/DT
efficiency/NN
of/IN
our/PRP$
experiments/NNS
through/IN
data/NNS
analysis/NN
./.
====================
We/PRP
then/RB
estimated/VBN
the/DT
number/NN
of/IN
consensus/NN
reads/VBZ
to/TO
be/VB
ready/RB
for/IN
more/RBR
accurate/JJ
variant/JJ
calling/JJ
./.
====================
Through/IN
this/DT
filtering/JJ
,/,
we/PRP
were/VBD
able/JJ
to/TO
get/VB
the/DT
consensus/NN
coverage/NN
down/RB
to/TO
one-sixth/DT
of/IN
the/DT
raw/NN
coverage/NN
(/(
Fig/NN
./.
====================
4/CD
)/)
./.
====================
According/VBG
to/TO
the/DT
filtering/JJ
methods/NNS
,/,
the/DT
consensus/NN
sequences/NNS
of/IN
each/DT
read/VBN
from/IN
different/JJ
UMI/NN
families/NNS
were/VBD
called/VBN
for/IN
scanning/NN
variants/NNS
./.
====================
In/IN
addition/NN
,/,
by/IN
calling/VBG
and/CC
filtering/VBG
consensus/NN
reads/VBZ
,/,
the/DT
probability/NN
of/IN
errors/NNS
was/VBD
considered/VBN
,/,
according/VBG
to/TO
the/DT
algorithm/NN
of/IN
the/DT
tool/NN
./.
====================
Furthermore/RB
,/,
the/DT
reads/VBZ
containing/VBG
Ns/NNS
or/CC
the/DT
reads/VBZ
with/IN
low/JJ
confidence/NN
were/VBD
filtered/VBN
out/RP
for/IN
highly/RB
confident/JJ
variant/JJ
calling/JJ
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
built/VBP
an/DT
analysis/NN
pipeline/NN
for/IN
targeted/VBN
sequencing/NN
data/NNS
generated/VBD
based/VBN
on/IN
the/DT
hybrid-capture/NN
method/NN
./.
====================
As/IN
UMI-adopted/JJ
targeted/VBN
sequencing/NN
data/NNS
are/VBP
notorious/JJ
for/IN
their/PRP$
novelty/NN
and/CC
complexity/NN
,/,
we/PRP
mainly/RB
focused/VBN
on/IN
finding/NN
tools/NNS
and/CC
optimizing/VBG
methods/NNS
for/IN
the/DT
analysis/NN
./.
====================
Our/PRP$
data/NNS
show/VBP
an/DT
on-target/JJ
rate/NN
of/IN
37/CD
%/NN
,/,
and/CC
there/EX
is/VBZ
little/JJ
variation/NN
among/IN
samples/NNS
./.
====================
This/DT
may/MD
suggest/VB
that/IN
almost/RB
equal/JJ
amounts/NNS
of/IN
libraries/NNS
of/IN
each/DT
sample/NN
were/VBD
used/VBN
for/IN
hybridization/NN
./.
====================
However/RB
,/,
because/IN
37/CD
%/NN
is/VBZ
relevantly/RB
low/JJ
for/IN
hybridization/NN
efficiency/NN
,/,
the/DT
estimation/NN
of/IN
the/DT
on-target/JJ
rates/NNS
shows/VBZ
that/IN
still/RB
there/EX
is/VBZ
room/JJ
for/IN
improvement/JJ
./.
====================
The/DT
reason/NN
why/WRB
on-target/JJ
rate/NN
is/VBZ
important/JJ
is/VBZ
that/DT
by/IN
estimating/VBG
on-target/JJ
rates/NNS
and/CC
further/RBR
upgrades/VBZ
of/IN
protocols/NNS
,/,
the/DT
quality/NN
of/IN
targeted/VBN
hybrid-capture/NN
sequencing/NN
could/MD
be/VB
improved/VBN
./.
====================
In/IN
detail/NN
,/,
protocol/NN
modifications/NNS
during/IN
hybridization/NN
steps/NNS
could/MD
possibly/RB
bring/VBG
about/RB
an/DT
increase/NN
of/IN
on-target/JJ
rates/NNS
./.
====================
For/IN
example/NN
,/,
a/DT
slightly/RB
excessive/JJ
amount/NN
of/IN
input/NN
DNA/NN
or/CC
target/NN
probes/NNS
can/MD
increase/VB
the/DT
off-target/NN
effects/NNS
during/IN
hybridization/NN
./.
====================
Furthermore/RB
,/,
inconsistent/JJ
temperature/NN
or/CC
slightly/RB
higher/lower/JJR
temperature/NN
than/IN
the/DT
proper/JJ
temperature/NN
could/MD
bring/VBG
about/RB
larger/JJR
off-target/RB
effects/NNS
than/IN
expected/VBN
./.
====================
With/IN
respect/NN
to/TO
the/DT
pipeline/NN
,/,
when/WRB
using/VBG
CallMolecular/JJ
ConsensusReads/NNS
,/,
insertion/NN
and/CC
deletion/NN
errors/NNS
are/VBP
not/RB
considered/VBN
in/IN
the/DT
consensus/NN
model/NN
./.
====================
Therefore/RB
,/,
realignment/JJ
steps/NNS
using/VBG
other/JJ
methods/NNS
,/,
such/JJ
as/IN
IndelRealigner/RB
(/(
GATK/NN
,/,
v4.0.2.1/NN
)/)
,/,
should/MD
be/VB
integrated/VBN
for/IN
better/RBR
and/CC
more/RBR
precise/JJ
analysis/NN
for/IN
identification/NN
of/IN
short/JJ
indels/VBZ
./.
====================
Furthermore/RB
,/,
even/RB
though/IN
we/PRP
optimized/VBD
the/DT
tools/NNS
and/CC
customized/VBD
python/NN
codes/VBZ
for/IN
analyzing/VBG
UMI/NN
data/NNS
,/,
there/EX
are/VBP
still/RB
many/JJ
tools/NNS
that/DT
could/MD
be/VB
used/VBN
in/IN
one/CD
analysis/NN
pipeline/NN
./.
====================
We/PRP
are/VBP
still/RB
trying/VBG
to/TO
minimize/VB
irrelevant/JJ
steps/NNS
to/TO
simplify/VB
the/DT
process/NN
./.
====================
In/IN
summary/NN
,/,
we/PRP
have/VBP
built/VBN
an/DT
analysis/NN
pipeline/NN
specialized/VBN
for/IN
UMI-adopted/JJ
hybrid-capture-based/VBD
data/NNS
./.
====================
Given/IN
the/DT
fact/NN
that/IN
the/DT
precision/NN
medicine/JJ
era/NNS
has/VBZ
been/VBN
coming/VBG
lately/RB
and/CC
that/IN
targeted/VBN
sequencing/NN
and/CC
UMI/NN
technology/NN
help/VBP
to/TO
comprehensively/RB
understand/CC
the/DT
genomewide/NN
status/NN
of/IN
cancer/NN
patients/NNS
,/,
this/DT
report/NN
suggests/VBZ
that/IN
the/DT
quality/NN
of/IN
the/DT
experiment/JJ
can/MD
be/VB
examined/VBN
precisely/RB
and/CC
efficiently/RB
by/IN
this/DT
pipeline/NN
,/,
and/CC
our/PRP$
laboratory/NN
sees/VBZ
its/PRP$
positive/JJ
potential/JJ
in/IN
being/VBG
widely/RB
used/VBN
for/IN
studies/NNS
in/IN
various/JJ
clinical/JJ
fields/NNS
./.
====================
Analysis/NN
pipeline/NN
./.
====================
Tools/NNS
and/CC
methods/NNS
used/VBN
in/IN
different/JJ
file/JJ
generation/NN
(/(
fastq/NN
to/TO
input/VB
files/NNS
for/IN
variant/JJ
calling/JJ
)/)
are/VBP
shown/VBN
in/IN
the/DT
flow/NN
chart/NN
./.
====================
Grouped/VBN
histogram/NN
of/IN
on-target/JJ
rate/NN
(/(
%/NN
)/)
./.
====================
On-target/RB
rate/NN
was/VBD
expressed/VBN
using/VBG
the/DT
stacked/JJ
histogram/NN
./.
====================
The/DT
x-axis/NN
shows/VBZ
6/CD
tumor/NN
samples/NNS
and/CC
one/CD
positive/JJ
control/NN
./.
====================
The/DT
upper/JJ
part/NN
of/IN
each/DT
bar/JJ
shows/VBZ
on-target/JJ
%/NN
when/WRB
the/DT
target/NN
region/NN
is/VBZ
enlarged/JJ
with/IN
additional/JJ
50-bp/JJ
flanking/JJ
parts/NNS
on/IN
both/CC
sides/NNS
of/IN
each/DT
region/NN
./.
====================
Duplicate/NN
rate/NN
./.
====================
Duplicate/NN
read/VBN
ratio/NN
of/IN
each/DT
sample/NN
./.
====================
Two/CD
positive/JJ
controls/NNS
are/VBP
shown/VBN
in/IN
the/DT
first/JJ
two/CD
samples/NNS
./.
====================
The/DT
average/JJ
duplicate/NN
rate/NN
is/VBZ
0.73/CD
./.
====================
Comparison/NN
of/IN
sequencing/NN
coverage/NN
from/IN
raw/NN
reads/VBZ
to/TO
filtered/JJ
reads/VBZ
./.
====================
The/DT
read/JJ
coverage/NN
calculated/VBN
from/IN
the/DT
read/JJ
counts/NNS
are/VBP
shown/VBN
with/IN
bar/JJ
plots/NNS
./.
====================
Read/RB
counts/NNS
and/CC
on-target/JJ
rates/NNS
(/(
%/NN
)/)
====================
